Supplementary Figure S2 from The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer

Authors :: Julie M. Bailis
Angela Coxon
Peter Kufer
Tobias Raum
Benno Rattel
Doris Rau
Katja Matthes
Michael Z. Liao
Matthias Friedrich
Famke Aeffner
Pamela Bogner
Joachim Wahl
Shyun Li
Olivier Nolan-Stevaux
Oliver Thomas
Petra Deegen
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: Figure S2. Enzalutamide increases PSMA expression levels and may enhance AMG 160-dependent cytotoxicity.

Full Text Access

Tools